PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Key Highlights
- ➤PacBio and TychoBio collaborate on AI models for rare disease RNA therapeutics
- ➤TychoBio plans to generate full-length RNA data from more than 10,000 samples
- ➤PacBio HiFi and Kinnex sequencing will link RNA compound designs to transcriptome effects
- ➤TychoBio will expand the approach from SBOs to siRNA and other RNA-targeting compounds
Expert Statements
Felix Raimundo, Founder and CEO of TychoBio
“AI models are only as good as the data they are trained on. To effectively identify new rare disease treatments, we needed the highest quality biological data, which can only be generated using PacBio HiFi sequencing technology.”
Felix Raimundo, Founder and CEO of TychoBio
“HiFi long read sequencing lets us see across full-length transcripts, including changes in isoforms and splicing of how the transcriptome is affected in rare diseases and which treatments could modify disease processes.”
Mark Van Oene, President and Chief Executive Officer of PacBio
“Our work with TychoBio, like our collaboration with Basecamp Research, highlights the critical value that high-quality sequencing data plays in generating the foundational data that will power biological modeling in the AI ecosystem.”
Mark Van Oene, President and Chief Executive Officer of PacBio
“We believe that this critical work will enable the development of transformative therapies that ultimately improve the lives of patients with rare diseases and their families.”
MENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio HiFi sequencing and Kinnex long-read RNA sequencing to generate data from more than 10,000 samples, building large-scale datasets linking the design of steric blocking antisense oligonucleotides (SBOs) to their effects across the transcriptome, with plans to expand the approach to siRNA and other RNA-targeting compounds.
TychoBio will test candidate RNA therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. Those results will become training data for models designed to predict which compounds are most likely to work, how long their effects may last, and where unintended effects may occur.
Get started
Create a free account to read the full story.